Premium
Polymorphisms in the 5α reductase type 2 gene and urologic measures of BPH
Author(s) -
Roberts Rosebud O.,
Bergstralh Erik J.,
Farmer Sara A.,
Jacobson Debra J.,
McGree Michaela E.,
Hebbring Scott J.,
Cunningham Julie M.,
Anderson Sarah A.,
Thibodeau Stephen N.,
Lieber Michael M.,
Jacobsen Steven J.
Publication year - 2004
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20142
Subject(s) - gene , medicine , 5 alpha reductase inhibitor , biology , genetics , prostate , finasteride , cancer
BACKGROUND The objective of the study was to examine associations between SRD5A2 polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS Participants were 510 Caucasian men (median age 60 years), randomly selected from the Olmsted County, MN community to participate in a longitudinal study of BPH. From 1990 through 2000, biennial measurements of lower urinary tract symptom severity (assessed from the American Urological Association Symptom Index, AUASI), peak urinary flow rates (Qmax), and prostate volume were made. Genotyping of SRD5A2 V89L, A49T, and TA repeat polymorphisms were performed. RESULTS Compared with the VV genotype, the LL genotype was associated with an enlarged prostate (Hazard ratio (HR) = 1.62, 95% confidence interval (CI) = 1.06, 2.43) but not with AUASI, Qmax, or PSA. The A49T and TA repeat polymorphisms were not associated with BPH. When the LL/VL, AT/TT, and TA(0)/TA(0) genotypes were considered high risk, the number of high risk genotypes increased with increasing prostate volume (32.3, 30.7, 34.1, and 38.7, respectively, P for trend = 0.04). CONCLUSIONS These findings do not demonstrate consistent associations between SRD5A2 genotypes and BPH. However, they suggest that the associations of V89L polymorphisms and prostate volume should be investigated further. © 2004 Wiley‐Liss, Inc.